Advertisement

Topics

Genentech's pediatric blood disorders drug under FDA priority review

05:58 EDT 13 Jun 2019 | SmartBrief

The FDA accepted under priority review status Roche unit Genentech's supplemental biologics license application for Rituxan,  -More

Original Article: Genentech's pediatric blood disorders drug under FDA priority review

NEXT ARTICLE

More From BioPortfolio on "Genentech's pediatric blood disorders drug under FDA priority review"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...